Zealand Pharma - Articles and news items

Phase I trial results for ZP4207 support its further development as a rescue treatment for severe hypoglycaemia

Industry news / 29 June 2015 / Victoria White

Zealand has announced results from a Phase I clinical trial of ZP4207 in severe hypoglycaemia in patients with diabetes…

zealand pharma

Zealand advances danegaptide into a Phase II clinical proof-of-concept study for protection against reperfusion injury

Industry news / 20 November 2013 / Zealand Pharma

Zealand Pharma A/S announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide…

Boehringer Ingelheim logo

Boehringer Ingelheim & Zealand Pharma enter into a licence & collaboration agreement

Industry news, News / 16 June 2011 / Boehringer Ingelheim

For dual-acting glucagon and GLP-1 receptor agonists…

Zealand Pharma Receives Milestone Payment from Helsinn Healthcare

Industry news, News / 9 December 2010 / M:Communications

Zealand Pharma, today announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...